Drug interactions
Liposomal doxorubicin + Nilotinib
Severity: Major
Liposomal doxorubicin and Nilotinib: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Nilotinib inhibits CYP3A4 and P-glycoprotein and may raise doxorubicin exposure. Both drugs affect cardiac function, and nilotinib prolongs the QT interval, so combined cardiac risk is a concern.
What this interaction means in plain words
Liposomal doxorubicin and Nilotinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Liposomal doxorubicin belongs to Oncology; Nilotinib belongs to Oncology.
Why it happens
CYP3A4 and P-glycoprotein inhibition by nilotinib, plus additive cardiotoxicity and QT effects.
What to do
Monitor ECG including QTc, electrolytes, LVEF and blood counts. Avoid the combination where alternatives exist.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Liposomal doxorubicin and Nilotinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Liposomal doxorubicin
- Dengue vaccine + Liposomal doxorubicin Contraindicated
- Belatacept + Liposomal doxorubicin Major
- Cyclosporine + Liposomal doxorubicin Major
- Dronedarone + Liposomal doxorubicin Major
- Elvitegravir / cobicistat / emtricitabine / tenofovir df + Liposomal doxorubicin Major
- Fingolimod + Liposomal doxorubicin Major
Other interactions of Nilotinib
- Amiodarone + Nilotinib Contraindicated
- Arsenic trioxide + Nilotinib Contraindicated
- Disopyramide + Nilotinib Contraindicated
- Dofetilide + Nilotinib Contraindicated
- Dronedarone + Nilotinib Contraindicated
- Droperidol + Nilotinib Contraindicated
Frequently asked questions
Can I take Liposomal doxorubicin with Nilotinib?
MediHelp rates the interaction as major. Liposomal doxorubicin and Nilotinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Nilotinib inhibits CYP3A4 and P-glycoprotein and may raise doxorubicin exposure. Both drugs affect cardiac function, and nilotinib prolongs the QT interval, so combined cardiac risk is a concern.
How serious is the interaction between Liposomal doxorubicin and Nilotinib?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor ECG including QTc, electrolytes, LVEF and blood counts. Avoid the combination where alternatives exist.
What other medicines interact with Liposomal doxorubicin?
MediHelp also lists interactions of Liposomal doxorubicin with, for example, Dengue vaccine, Belatacept, Cyclosporine. The full list is on the Liposomal doxorubicin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
